{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:59Z","timestamp":1792036859537,"version":"4.4.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Fujian Province of China"},{"name":"Joint Funds for the Innovation of Science and Technology of Fujian provinc"},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fujian Provincial Clinical Research Center for Hematological Malignancies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01675-5","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T12:10:01Z","timestamp":1740831001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting"],"prefix":"10.1186","volume":"18","author":[{"given":"Huijian","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajian","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renyao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenshu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"issue":"1","key":"1675_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang TB, Liu DL. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13(1):125.","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"1675_CR2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2024-200336","volume":"144","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone vs. Daratumumab, Bortezomib, and Dexamethasone in Relapsed\/Refractory multiple myeloma: overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 Trial. Blood. 2024;144(Supplement 1):772.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1675_CR3","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1182\/blood-2024-201543","volume":"144","author":"V Hungria","year":"2024","unstructured":"Hungria V, Hus M, Robak P, Zherebtsova V, Ribas ACDA, Lacerda MPD, et al. Efficacy outcomes by minimal residual disease (MRD) negativity in patients with relapsed or refractory multiple myeloma treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone vs. Daratumumab, Bortezomib, and Dexamethasone: analysis from the Dreamm-7 Trial. Blood. 2024;144(Supplement 1):3359.","journal-title":"Blood"},{"key":"1675_CR4","doi-asserted-by":"crossref","unstructured":"Beksac M, Garcia EG, Delimpasi S, Robak P, Karunanithi K, Arriba FD, et al. Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs. Pomalidomide Plus Bortezomib and Dexamethasone in patients with Relapsed\/Refractory multiple myeloma: a subset analysis in patients who have received 1 prior line of Therapy Including Lenalidomide. Blood.2024;144 (Supplement 1): 4731.","DOI":"10.1182\/blood-2024-199282"},{"issue":"Supplement 1","key":"1675_CR5","first-page":"497","volume":"144","author":"SZ Usmani","year":"2024","unstructured":"Usmani SZ, Mielnik M, Garg M, Sandhu I,Abdallah AO,Koh Y, et al. Phase I study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible newly diagnosed multiple myeloma: Dreamm-9. Updated Interim Anal Blood. 2024;144(Supplement 1):497.","journal-title":"Updated Interim Anal Blood"},{"key":"1675_CR6","doi-asserted-by":"crossref","unstructured":"D\u2019Souza A, LCosta LJ, San-Miguel JF, Berdeja JG, Giles DM, Touzeau C et al. Teclistamab, Daratumumab, and Pomalidomide in patients with Relapsed\/Refractory multiple myeloma: results from the Majestec-2 Cohort a and Trimm-2 Studies.Blood.2024;144 (Supplement 1): 495.","DOI":"10.1182\/blood-2024-200181"},{"key":"1675_CR7","doi-asserted-by":"crossref","unstructured":"Zamagni E, Silzle T,\u0160pi\u010dka I,Tahri SLS, Nijhof. IS,phase 3 study of Teclistamab (Tec) in combination with Lenalidomide (Len) and tec alone Versus Len alone in newly diagnosed multiple myeloma (NDMM) as maintenance therapy following autologous stem cell transplantation (ASCT): safety run-in (SRI) results from the Majestec-4\/EMN30 Trial.Blood.2024;144 (Supplement 1): 494.","DOI":"10.1182\/blood-2024-205608"},{"key":"1675_CR8","doi-asserted-by":"crossref","unstructured":"Raab MS. Weinhold N,Kort\u00fcm KM,Kr\u00f6nke J,Podola L,Bertsch U,Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) Trial.Blood.2024;144 (Supplement 1): 493.","DOI":"10.1182\/blood-2024-206003"},{"key":"1675_CR9","doi-asserted-by":"crossref","unstructured":"Popat R, Oriol A, Cavo M, Karlin L, Mazza IA, Roeloffzen W et al. Ciltacabtagene Autoleucel (Cilta-cel) vs Standard of Care (SoC) in patients with Lenalidomide (Len)-Refractory multiple myeloma (MM) after 1\u20133 lines of therapy: minimal residual disease (MRD) negativity in the phase 3 Cartitude-4 Trial. Blood.2024;144 (Supplement 1): 1032.","DOI":"10.1182\/blood-2024-201533"},{"key":"1675_CR10","doi-asserted-by":"crossref","unstructured":"Bishop MR, Rosenblatt J, Dhakal B,Raje NCD, Gaballa. MR,phase 1 study of Anitocabtagene Autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma (RRMM): efficacy and safety with 34-Month median Follow-up.Blood.2024;144 (Supplement 1): 4825.","DOI":"10.1182\/blood-2024-201080"},{"key":"1675_CR11","doi-asserted-by":"crossref","unstructured":"Freeman CL, Dhakal B, Kaur G, Maziarz RT, Callander N, Sperling AS, et al. Phase 2 Registrational Study of Anitocabtagene Autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: preliminary results from the IMMagine-1 trial. Blood. 2024;144(Supplement 1):1031.","DOI":"10.1182\/blood-2024-198499"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01675-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01675-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01675-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T12:10:12Z","timestamp":1740831012000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01675-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1675"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01675-5","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable for this summary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for this summary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}